GPX-100 (13-deoxydoxorubicin)

TERMINATED · PHASE2 · Breast Cancer, Metastasis

Unknown stopping reason

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.